Replies to post #6964 on The Rising Influence of Rising Affluence

[DewDiligence]

PFE—According to today's 1Q13 CC, the $0.06 reduction in 2013 non-GAAP EPS guidance (to $2.14-2.24 from the old range of $2.20-2.30) was due solely to two items: i) currency (especially the weakening of the yen relative to the US dollar); and ii) the timing of the ZTS IPO.

[DewDiligence]

PFE and The Global Demographic Tailwind:

http://finance.yahoo.com/news/pfizers-ceo-discusses-q1-2013-165608862.html

During the first quarter, biopharmaceutical volume [grew]10% in the BRIC-MT* markets…primarily driven by strong growth in China and partially offset by price reductions of 1% to these markets…

If you exclude the product portfolio of products whose rights were transferred to our joint venture in China with Hisun, our operational revenue growth would have been 8% in our emerging markets business, 14% in BRIC-MT countries and 31% in China.

*Brazil, Russia, India, China, Mexico, Turkey.